Explore effectiveness results in LEOPOLD I
In LEOPOLD I, doctors studied annual bleed rate (ABR) with KOVALTRY® , choosing either 2x/week prophylaxis (18 people) or 3x/week prophylaxis (44 people) based on people's needs1
PEOPLE IN THE STUDY2
ASSIGNED DOSING2
ABR RESULTS1
Group 1 (18 people)
generally began the study with
fewer bleeds and a lower
percentage of target joints
2x/week
median ABR
Group 2 (44 people)
generally began the study with
more bleeds and a higher
percentage of target joints
3x/week
median ABR
In LEOPOLD I, doctors studied annual bleed rate (ABR) with KOVALTRY® , choosing either 2x/week prophylaxis (18 people) or 3x/week prophylaxis (44 people) based on people's needs1
PEOPLE IN THE STUDY2
Group 1 (18 people)
generally began the study with fewer bleeds and a lower percentage of target joints
ASSIGNED DOSING2
2x/week
ABR RESULTS1
median ABR
PEOPLE IN THE STUDY2
Group 2 (44 people)
generally began the study with more bleeds and a higher percentage of target joints
ASSIGNED DOSING2
3x/week
ABR RESULTS1
median ABR
When treating on demandOn-demand treatment in hemophilia A is treatment of bleeds as they happen., 87% of bleeding episodes were resolved with 2 or fewer infusions of KOVALTRY® in LEOPOLD I.1
INDICATION FOR KOVALTRY®
KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.
KOVALTRY is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY when you have surgery.
KOVALTRY is not used to treat von Willebrand Disease.
IMPORTANT SAFETY INFORMATION
You should not use KOVALTRY if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY.
Tell your healthcare provider if you have heart disease or are at risk for heart disease.
The common side effects of KOVALTRY are fever, headache, and rash, in addition to inhibitors in patients who were not previously treated or minimally treated with Factor VIII products.
Your body may make antibodies, called “inhibitors” against KOVALTRY, which may stop KOVALTRY from working properly. If your bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.
Allergic reactions may occur with KOVALTRY. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.
Tell your healthcare provider about any side effect that bothers you or that does not go away.
Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY.
For additional important risk and use information, please see full Prescribing Information.
References: 1. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2021. 2. Data on file. Bayer HealthCare Pharmaceuticals, Inc; 2016.
